UMB 425 is being called a breakthrough in the development of therapeutics to treat chronic pain, acts on two different opioid receptors with diminished tolerance over time and no obvious toxic effects.
A team of researchers led by Andrew Coop, PhD, professor and chair of the Department of Pharmaceutical Sciences (PSC) at the University of Maryland School of Pharmacy (UMSOP), has developed a new opioid drug that shows great potential to advance treatment and improve quality of life for individuals living with chronic pain. Spotlighted in a recent issue of ACS Chemical Neuroscience, the compound, known as UMB 425, is as strong as morphine, but displays diminished tolerance over time with no obvious toxic effects.
“UMB 425 is a breakthrough in the development of therapeutics to treat chronic pain,” says Coop. “Unlike other drugs developed to act on only one biological target, UMB 425 acts on two different opioid receptors in the body. When activated at the same time, these receptors work together to provide pain relief and slow the body’s development of tolerance to the drug. This diminished tolerance allows a lower dose of the opioid to be administered for a longer time period, while still achieving the same level of pain relief.”
For individuals living with chronic pain, either as a result of injury or disease such as arthritis, opioids are the standard treatment. But as the dosage increases to offset the body’s tolerance to their effects, opioids cause a number of adverse effects, including constipation, nausea, drowsiness, and dizziness. The unique dual-profile of UMB 425 – made possible through Coop’s collaborations with Alexander MacKerell, PhD, professor in PSC and director of the School’s Computer Aided Drug Design Center, and Maureen Kane, PhD, assistant professor in PSC and co-director of the School’s Mass Spectrometry Facility – provides both pain relief as well as diminished tolerance in one drug.
“Historically, medicinal chemists have developed drugs aimed at only one biological target,” says Coop. “However, two drugs administered together have the potential to metabolize differently in different individuals, as well as affect patients’ adherence to both drugs. A single compound that is able to provide both pain relief and diminished tolerance has the advantage of a defined ratio that we can optimize to ensure patients receive the maximum pain relief, while experiencing minimum adverse effects.”
Coop and his team conducted several in vitro and in vivostudies to determine the drug’s effectiveness in alleviating pain and diminishing tolerance over time. If future research and clinical trials are successful, UMB 425 could have a significant impact on the treatment and quality of life for individuals living with chronic pain.
“The clinical implication of this research has the potential to be tremendous,” says Mary Lynn McPherson, PharmD, BCPS, CPE, professor and vice chair for academic affairs in the Department of Pharmacy Practice and Science, and an international authority in the fields of pain management and palliative care. “If clinicians can prescribe lower doses of opioids, they will not have to raise a patient’s dose because of tolerance to the analgesic effects. Using lower doses will result in less severe adverse effects for the patient, both short-term effects such as nausea and constipation, as well as long-term adverse effects on the endocrine and immunologic systems. This would be a highly significant advance in pain management.”
The Latest on: Chronic Pain
- Chronic Pain Treatment Coverage Varies Widely on October 5, 2018 at 2:10 pm
Health insurers did not have clear, consistent policy terms to treat chronic pain with non-drug treatments, a cross-sectional study of 2017 U.S. private and public insurance plans showed. While most p... […]
- Chronic Pain Management: Finding the Right Treatment Mix on October 5, 2018 at 8:07 am
Chronic pain relief is a bit like major weight loss: It takes time, effort and often multiple methods to get noticeable results. Pain, like excess weight, is harder to shed when you've had it for ... […]
- Abattis Unveils “Comfort”, Its Proprietary New Chronic Pain and Inflammation Product to Start Shipping November 2018 on October 4, 2018 at 6:19 pm
VANCOUVER, British Columbia, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce the pending release of ... […]
- Ochsner gets $1.6M for chronic pain management study on October 4, 2018 at 2:03 pm
Ochsner Heath System has been awarded $1.6 million to further study how to help patients manage chronic pain while mitigating the risk of opioid abuse. The grant from the National Institutes of Health ... […]
- More than opioids: St. Cloud health care providers explore new terrain for pain patients on October 4, 2018 at 12:40 pm
Check out this story on sctimes.com: https://www.sctimes.com/story/news/2018/10/04/new-terrain-pain-management-st-cloud-va-addiction-chronic-veterans-miles-belgrade-neurology/1447717002/ […]
- Nonaddictive drug compound could replace opioids for chronic pain sufferers on October 4, 2018 at 9:40 am
WEST LAFAYETTE, Ind. – A new nonaddictive drug compound discovered by Purdue University researchers could lead to the treatment of chronic pain without the need to rely on opioids, just as a bipartisa... […]
- BioElectronics Announces Publication of Electroceuticals Article on Chronic Pain on October 4, 2018 at 5:30 am
FREDERICK, MD, Oct. 04, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioElectronics Corporation (OTC Pink: BIEL), the maker of non-invasive electroceutical devices, announced the publication of an ... […]
- The Use of Cannabis to Treat Chronic Pain on October 3, 2018 at 10:30 pm
Chronic pain can lead to depression, addiction to opioids, anxiety, other side effects, and more. The first video from Howcast talks about clinical trials being conducted with cannabis and cannabinoid... […]
- NIH director: US needs more treatments for opioid addiction, chronic pain on October 3, 2018 at 4:04 pm
The head of the National Institutes of Health said Wednesday that science can help the nation find newer and smarter ways out of an epidemic that resulted in more than 49,000 opioid overdose deaths la... […]
- Sugar Pill Just Might Control Your Chronic Pain on October 3, 2018 at 1:30 am
Researchers have developed a way to reliably predict which chronic pain patients will respond to a sugar placebo pill based on brain anatomy and psychological characteristics. Doctors may one day pres... […]
via Google News and Bing News